Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Christine L Phillips, MD, Stella M. Davies, MBBS, PhD, Richard McMasters, MD, Maureen O'Brien, MD, MS, Michael J. Absalon, MD, PhD, Jeffrey A. Moscow, MD, Teresa Smolarek, PhD, John P. Perentesis, MD

Blood (2010) 116 (21): 1070.

https://doi.org/10.1182/blood.V116.21.1070.1070

Published: 2010

Journal Articles

Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML.

Alex George, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Soheil Meshinchi, MD, Julie A. Ross, PhD, John P. Perentesis, MD, Stella M. Davies, MD PhD

Blood (2007) 110 (11): 1444.

https://doi.org/10.1182/blood.V110.11.1444.1444

Published: 2007

Journal Articles

Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.

John P. Perentesis, MD, Doojduen Villaluna, MS, Stella M. Davies, MBBS, PhD, Xiaowen Zhai, MD, PhD, Gretchen A. Radloff, MS, Michael A. Weiner, MD, Richard Sposto, PhD, Kara M. Kelly, MD

Blood (2006) 108 (11): 100.

https://doi.org/10.1182/blood.V108.11.100.100

Published: 2006

Journal Articles

Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.

Deepika Bhatla, MD, Robert B. Gerbing, MS, Heather D. Conner, BS, Todd A. Alonzo, PhD, Xiaowen Zhai, MD, Parinda Mehta, MD, Julie A. Ross, PhD, Hartmut Geiger, PhD, Beverly J. Lange, MD, John P. Perentesis, MD, Stella M. Davies, MBBS, PhD

Blood (2006) 108 (11): 17.

https://doi.org/10.1182/blood.V108.11.17.17

Published: 2006

Journal Articles

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Mukta Sharma, MD, Todd A. Alonzo, PhD, April Sorrell, MD, Robert B. Gerbing, MA, Joanne M. Hilden, MD, Robert J. Arceci, MD, PhD, Gita Massey, MD, John J. Doyle, MD, Lisa Bayer, CPNP, John P. Perentesis, MD, Julie Ross, PhD, Franklin O. Smith, MD, Russell Brynes, MD, Jerry Hussong, MD, Lois Hathaway, Alan Gamis, MD

Blood (2006) 108 (11): 376.

https://doi.org/10.1182/blood.V108.11.376.376

Published: 2006

NARROW

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML.

Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.

Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Email alerts

ASH Publications

American Society of Hematology

Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.

Polymorphisms in the MGMT Gene as Predictors of Leukemia Risk and Response to Therapy in Children with AML.

Pharmacogenetic Predictors of Toxicity in Dose-Intensive Therapy for Pediatric Advanced-Stage Hodgkin’s Lymphoma.

Cytidine Deaminase Genotype Modifies the Toxicity of Therapy for Childhood AML.

Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only